Trial Profile

A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erfonrilimab (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

07 Jun 2023 Status changed from active, no longer recruiting to completed.
10 Dec 2022 Results(As of May 9, 2022; n=27 ) assessing Efficacy, Safety, and Tolerability of KN046 in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer presented at the 45th Annual San Antonio Breast Cancer Symposium
16 Nov 2021 Planned End Date changed from 15 Sep 2021 to 15 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com